Yinguo Lin

Q: What is Yin-guo Lin email address?

Email Yin-guo Lin at ylin19382@hotmail.com and lin_yinguo@lilly.com. This email is the most updated Yin-guo Lin's email found in 2026.

Q: How to contact Yin-guo Lin?

To contact Yin-guo Lin send an email to ylin19382@hotmail.com or lin_yinguo@lilly.com. (updated on September 05, 2024)

Research Scientist at Eli Lilly and Company | West Chester, Pennsylvania, United States

About Yinguo Lin

Yin-guo Lin is a dedicated Research Scientist at Eli Lilly and Company, where he leverages his extensive expertise in drug discovery, particularly within the realms of neuroscience and inflammation pain. With a robust background in histology and histopathology, Yin-guo plays a pivotal role in advancing the company's research initiatives aimed at developing innovative therapeutic solutions for neurodegenerative diseases. His current focus involves the development and execution of in vivo and in vitro screening of potential PET tracers, utilizing advanced imaging techniques such as micro-PET/CT and ARG to assess brain tissue affected by various neurodegenerative conditions.

Yin-guo's proficiency in microscopy, image processing, and quantification allows him to extract meaningful insights from complex biological data, enhancing the understanding of disease mechanisms and treatment efficacy. His hands-on experience with animal surgery and drug formulation—administering compounds via intraperitoneal (ip), oral (po), subcutaneous (sc), and intracerebroventricular (icv) routes—enables him to design and conduct rigorous preclinical studies. Notably, he has successfully conducted the in-life portion of rodent metabolism and biodistribution studies, contributing to the evaluation of pharmacokinetics and safety profiles of novel compounds.

In addition to his technical skills in immunohistochemistry and electrophysiological methods, Yin-guo's collaborative spirit and commitment to scientific excellence make him an invaluable asset to the discovery research team at Eli Lilly. His work not only supports the development of new pain management therapies but also aligns with the company's broader mission to address unmet medical needs in oncology and beyond. As he continues to explore the intricate interplay between drug action and neurobiology, Yin-guo remains at the forefront of pioneering research that holds the potential to transform patient care.

Yinguo Lin Work

Research Scientist at Eli Lilly and Company in January 2016 to Present

Research Scientist, In Pharmacology at Avid Radiopharmaceuticals, Inc. a wholly owned subsidiary of Eli Lilly and Company in July 2012 to December 2015

Research Specialist, Dept. of Neurosurgery and Center for Brain Injury and Repair at Perelman School of Medicine at the University of Pennsylvania in March 2010 to July 2012